Oryzon to Attend the 36th Annual Cowen Health Care Conference
23 févr. 2016 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
16 févr. 2016 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics to Present at the 18th Annual BIO CEO & Investor Conference 2016
02 févr. 2016 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
01 févr. 2016 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics to Present at the Epigenetics in Drug Discovery Workshop
26 janv. 2016 16h30 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
05 janv. 2016 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors
30 déc. 2015 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Dec. 30, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics – ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Files Clinical Trial Application in Spain for Phase I Study With ORY-2001 for Alzheimer’s Disease
16 déc. 2015 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics - ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics Announces Listing on Madrid Stock Exchange
10 déc. 2015 08h14 HE
|
Oryzon
Company valued at approximately EUR 100 million
Priced at EUR 3.39 per share
Founders, Carlos Buesa and Tamara Maes, control 26.3% of shares outstanding
BARCELONA,...
ORYZON to Present at the Neuroscience R&D Technologies Conference
30 nov. 2015 08h00 HE
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...